Dulaglutide
- Generic Name
- Dulaglutide
- Brand Names
- Trulicity
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 923950-08-7
- Unique Ingredient Identifier
- WTT295HSY5
- Background
Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was appro...
- Indication
Dulaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years of age with type 2 diabetes mellitus. It is also indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular r...
- Associated Conditions
- Major Adverse Cardiovascular Events, Type 2 Diabetes Mellitus
- Associated Therapies
- -
A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)
- Conditions
- Interventions
- First Posted Date
- 2019-10-29
- Last Posted Date
- 2021-01-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 72
- Registration Number
- NCT04143802
- Locations
- 🇺🇸
Clinical Trials of Texas, Inc., San Antonio, Texas, United States
🇺🇸Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸PRA International, Lenexa, Kansas, United States
A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes
- First Posted Date
- 2019-03-04
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 636
- Registration Number
- NCT03861052
- Locations
- 🇯🇵
Medical Corporation Chiseikai Tokyo Center Clinic, Chuo-ku, Tokyo, Japan
🇯🇵Ikebukuro Metropolitan Clinic, Toshima-ku, Tokyo, Japan
🇯🇵IHL Shinagawa East One Medical Clinic, Minato-ku, Tokyo, Japan
Dulaglutide in Diabetic Patients, Relationship Between Arterial Stiffness, Endothelial Function, Clinical and Laboratory Variables
- Conditions
- Interventions
- First Posted Date
- 2019-01-31
- Last Posted Date
- 2019-01-31
- Lead Sponsor
- University of Palermo
- Target Recruit Count
- 92
- Registration Number
- NCT03824002
- Locations
- 🇮🇹
Internal Medicine Ward, University of Palermo, Palermo, Italy
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
- Conditions
- Interventions
- First Posted Date
- 2018-09-26
- Last Posted Date
- 2021-11-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 908
- Registration Number
- NCT03684642
- Locations
- 🇺🇸
Investigational Site Number 8400009, Los Angeles, California, United States
🇺🇸Investigational Site Number 8400059, Skokie, Illinois, United States
🇺🇸Investigational Site Number 8400061, Boston, Massachusetts, United States
Dulaglutide and Insulin MicrosecretiON in Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2021-07-08
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 45
- Registration Number
- NCT03668470
- Locations
- 🇫🇷
Service d'Endocrinologie, Maladies Métaboliques et Nutrition,CHU Nantes,Hôpital Nord Laennec,Bd Jacques-Monod,Saint-Herblain, NANTES cedex 1, France
🇫🇷Service d'Endocrinologie, Maladies Métaboliques et Nutrition, CHU Grenoble, Hopital de la Tronche, La Tronche, France
🇫🇷Département d''Endocrinologie, Diabétologie, Nutrition ; CHU Montpellier ; Hôpital Lapeyronie, Avenue du Doyen Giraud, Montpellier 5, France
Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
- Conditions
- Interventions
- First Posted Date
- 2018-07-18
- Last Posted Date
- 2020-02-20
- Lead Sponsor
- Medanta, The Medicity, India
- Target Recruit Count
- 60
- Registration Number
- NCT03590626
- Locations
- 🇮🇳
Division Of Endocrinology & Diabetes, Medanta The Medicity, Gurgaon, Haryana, India
A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes
- First Posted Date
- 2018-04-11
- Last Posted Date
- 2020-06-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1842
- Registration Number
- NCT03495102
- Locations
- 🇺🇸
Artemis Institute for Clinical Research, San Diego, California, United States
🇺🇸University Clinical Investigators, Inc., Tustin, California, United States
🇺🇸Saltzer Medical Group. P.A., Nampa, Idaho, United States
Effect of Exenatide LAR or Dulaglutide on the Variability of 24-hour Heart Rate and Blood Pressure in Type 2 Diabetes
- First Posted Date
- 2018-02-23
- Last Posted Date
- 2020-03-26
- Lead Sponsor
- University of Guadalajara
- Target Recruit Count
- 30
- Registration Number
- NCT03444142
- Locations
- 🇲🇽
Instituto de terapeutica Experimental y Clinica. Centro universitario de Ciencias de la Salud. Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes
- First Posted Date
- 2017-10-20
- Last Posted Date
- 2019-09-16
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 12
- Registration Number
- NCT03315780
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan
Smoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) Analogues
- Conditions
- Interventions
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2022-09-13
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 256
- Registration Number
- NCT03204396
- Locations
- 🇨🇭
Universitätsspital Basel, Basel, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.